Noradrenergic Drug Market size was over USD 17.03 billion in 2024 and is projected to reach USD 24.7 billion by 2037, witnessing around 2.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of noradrenergic drug is assessed at USD 17.83 billion.
The growth of the market can be attributed to the growing prevalence of mental disorders across the globe. Norepinephrine drugs are used to treat the symptoms of different mental health issues. These drugs control the body's levels of neurotransmitters and increase alertness and concentration. According to estimates, more than 7% of Indians suffer from some mental disorder.
In addition to these, factors that are believed to fuel the market growth of noradrenergic drugs include the rising lifestyle disorders. For instance, high-stress conditions can lead to several disorders such as anxiety, depression, blood pressure, and cardiovascular diseases. Noradrenaline drugs can be utilized to treat anxiety and depression. Further, mood and attentiveness are all impacted by norepinephrine. Additionally, the growing prevalence of Attention-deficit/hyperactivity disorder (ADHD) is predicted to present the potential for market expansion over the projected period.
Growth Drivers
Growing Prevalence of Autism – On account of the growing awareness and screening of autism spectrum disorder, the market is expected to expand more in the upcoming years. According to the World Health Organization (WHO), one in 100 children globally suffers from autism.
Rising Geriatric Population – Elderly population is more prone to dementia and the rising number of elderly populations across the globe is estimated to drive market growth. In 2020, there were more people over the age of 60 than children under five, and by 2050, it is predicted that 80% of the world's old people will live in low- and middle-income countries.
Surging Incidences of Hypertension – According to the most recent data, more than 40% with uncontrolled hypertension have a blood pressure of 140/90 mmHg or higher.
Increasing Diseases such as Obesity and Diabetes – It is expected that patients with obesity or diabetes are likely to be more susceptible to heart disease, diabetes, and high blood pressure, which is anticipated to drive the market growth. It was discovered that over 30 million Americans, suffered from diabetes in 2019.
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
2.9% |
|
Base Year Market Size (2024) |
USD 17.03 billion |
|
Forecast Year Market Size (2037) |
USD 24.7 billion |
|
Regional Scope |
|
Application (Hyperactivity Depressant, Control Aggression, High Blood Pressure)
The global noradrenergic drug market is segmented and analyzed for demand and supply by application into hyperactivity depressants, control aggression, high blood pressure, and others. Out of the four applications, the hyperactivity depressant segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of attention deficit/hyperactivity disorder (ADHD) among all age groups. For instance, ADHD can cause hyperactivity and difficulties in concentrating. For the treatment of anxiety, depression, and occasionally attention deficit hyperactivity disorder symptoms, norepinephrine reuptake inhibitors (NRIs) are frequently given. Further, by raising norepinephrine levels in the brain, NRIs are used to treat ADHD and regulate hyperactivity. According to a survey, more than 11% of primary school students in India have ADHD.
Distribution Channel (Hospital Pharmacy, Drug Stores, Online Pharmacies)
The global noradrenergic drug market is also segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, drug stores, online pharmacies, and others. Amongst these four segments, the hospital pharmacies segment is expected to garner a significant share. It is simpler and more practical for patients with diabetes, high blood pressure, and other mental problems to buy the necessary medications right there on the hospital grounds rather than having to travel to another facility for their care. Further, the increasing attention paid to patient care programs to help children with autism, such as the Autism Center Partial Hospital Program and Autism Inpatient Care, in turn, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Application |
|
|
By Distribution Channel |
|
APAC Market Statistics
The Asia Pacific industry is estimated to account for largest revenue share of 37% by 2037. The growth of the market can be attributed majorly to the increasing popularity of antidepressants among the adult population in the region. For instance, an increasing number of adults across Asia are affected with diagnosable mental illnesses, owing to stressful life events, such as money issues, the death of a loved one, or a divorce. These days, antidepressants are one of the drugs that are most frequently prescribed, especially to elderly people. Noradrenergic drugs are used largely as antidepressants. They are utilized as a treatment for several ailments, such as ADHD, depression, and low blood pressure. Further, among people with major depressive illness, antidepressants are more effective. In addition, rising depressive disorders in the region, are also anticipated to boost the market growth during the forecast period. Over 2% of the adult population in Singapore, and more than 10% in Vietnam & Thailand suffer from a diagnosable mental disorder at any given time.
North American Market Forecast
The North American noradrenergic drug market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the rising numbers of people with autism spectrum disorders (ASD). For instance, an increase in ASD cases, particularly in the population of children, and the introduction and quick acceptance of several ASD medications in the region, are also anticipated to contribute to the market growth in the region. Moreover, given that noradrenergic drugs are used to treat autism, the demand for them in the region is anticipated to rise. In 2018, more than 2% of American children, were diagnosed with an autism spectrum disorder.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the growing awareness of mental disorders. For instance, anxiety disorder is the most prevalent mental illness among EU nations. The social and financial repercussions of mental health issues are becoming more widely recognized in the region. Further, the European Mental Health Action Plan puts a strong emphasis on seven interconnected goals and suggests practical solutions to improve mental health and well-being. In addition, the region's expanding healthcare industry is also anticipated to boost market growth during the forecast period.
Baxter International, Inc. introduced premix Norepinephrine Bitartrate in 5% Dextrose Injection, which can be can be kept in automated dispensing cabinets at the point-of-care and has a shelf life of up to 21 months in the refrigerator or up to 90 days at room temperature in overwrap. Further, it is used to treat individuals with acute or emergent hypotension
Sanofi-aventis Groupe acquired Provention Bio, Inc., to add TZIELD, the first disease-modifying therapy for the postponement of Stage 3 type 1 diabetes, to the portfolio. Further, the drug TZIELD (teplizumab-mzwv) can be used to postpone the onset of Stage 3 type 1 diabetes (T1D) in adults and children with Stage 2 T1D who are at least 8 years old.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?